Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 20% Improvement Relative Risk Krishnan et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 152 patients in the USA Lower mortality with HCQ (not stat. sig., p=0.48) Krishnan et al., J Clin Anesth., doi:10.1016/j.jclinane.2020.110005 Favors HCQ Favors control
Clinical comorbidities, characteristics, and outcomes of mechanically ventilated patients in the State of Michigan with SARS-CoV-2 pneumonia
Krishnan et al., J Clin Anesth., doi:10.1016/j.jclinane.2020.110005
Krishnan et al., Clinical comorbidities, characteristics, and outcomes of mechanically ventilated patients in the State of.., J Clin Anesth., doi:10.1016/j.jclinane.2020.110005
Jul 2020   Source   PDF  
  All Studies   Meta
Retrospective 152 mechanically ventilated patients in the USA showing unadjusted lower mortality with vitamin C, vitamin D, HCQ, and zinc treatment, statistically significant only for vitamin C.
Although the 20% lower mortality is not statistically significant, it is consistent with the significant 22% lower mortality [18‑27%] from meta analysis of the 232 mortality results to date. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 20.4% lower, RR 0.80, p = 0.48, treatment 86 of 144 (59.7%), control 6 of 8 (75.0%), NNT 6.5.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Krishnan et al., 20 Jul 2020, retrospective, USA, peer-reviewed, 13 authors, dosage not specified.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Journal of Clinical Anesthesia 67 (2020) 110005 Contents lists available at ScienceDirect Journal of Clinical Anesthesia journal homepage: Correspondence Clinical comorbidities, characteristics, and outcomes of mechanically ventilated patients in the State of Michigan with SARS-CoV-2 pneumonia In December 2019, a series of viral infections, eventually named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appeared in China and quickly spread across the world [1]. The United States (USA) has been profoundly affected, reporting the most confirmed cases of SARS-CoV-2 of any country. As of June 10, 2020, SARSCoV-2 infection has been confirmed in more than 7.3 million individuals in 188 countries and regions, with an overall mortality rate of more than 5.7% [2]. The State of Michigan has been particularly devastated by this disease; it ranks 9th in the USA with 65,182 total confirmed cases of SARS-CoV-2 and 6th in the USA with 5955 total deaths [2]. While the clinical course of patients with SARS-CoV-2 infection can vary from completely asymptomatic to critically ill, an understanding of differing patient characteristics and outcomes of infected patients is critical for health and government officials engaged in planning efforts to address outbreaks. We sought to describe the demographics, baseline comorbidities, and outcomes in patients with SARS-CoV-2 who required mechanical ventilation from a single hospital system in the state of Michigan, USA. This retrospective observational study was conducted at St. Joseph Mercy Oakland Hospital, and data were obtained from medical records from the 7 hospitals in the health system (1996 beds). The institutional review board approved the study as minimal-risk research using data collected for routine clinical practice and waived the requirement for informed consent. All consecutive patients from March 10, 2020 to April 15, 2020 who required hospital admission with confirmed SARSCoV-2 infection by positive result on polymerase chain reaction (PCR) T testing of a nasopharyngeal sample were included in this study. The focus of this study was SARS-CoV-2 patients who required mechanical ventilation in the Intensive Care Unit (ICU), and only patients who completed their hospital course within the health system at study end (discharged alive or dead) were included in the study. During the study period a total of 901 adult patients with confirmed SARS-CoV-2 infection were admitted to the 7 hospitals within the health system. After initial chart review 152 patients requiring mechanical ventilation were included. Of the 152 mechanically ventilated patients with confirmed SARS-CoV-2 infection, 39% (60)..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop